Form 4: Corcept Therapeutics Executive Gary Charles Robb Reports Changes in Beneficial Ownership

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports changes in beneficial ownership of company stock due to gift transactions.

Summary

• On March 12, 2025, Gary Charles Robb, the Chief Business Officer of Corcept Therapeutics, reported changes in his beneficial ownership of Corcept Therapeutics common stock.
• He gifted 4,625 shares of common stock.
• He also reported acquisitions of 1,000 shares each in custodial accounts for his children.
• Following these transactions, Robb directly owns 18,865 shares and indirectly owns 10,665 shares in each of the two custodial accounts.
• The direct holdings include 1,818 shares underlying unvested restricted stock awards granted on June 3, 2024, 503 shares granted on September 3, 2024, 290 shares granted on December 2, 2024, and 292 shares granted on March 3, 2025, which vest on the one-year anniversary of the grant date.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to changes in beneficial ownership by a company executive, which is a common occurrence in publicly traded companies. It provides transparency to investors regarding insider transactions.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions, which can influence investor confidence.

Key Dates